Defence Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTC.CN research report →
Price Chart
About the company
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases.
- CEO
- Amie Phinney
- IPO
- 2021
- Employees
- 5
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on DTC.CN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $37.52M
- P/E
- -4.43
- PEG
- 0.11
- P/S
- 0.00
- P/B
- 5.40
- EV/EBITDA
- -6.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1661.38%
- ROIC
- -53.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-72,338+20.4%
- Op Income
- $-3,268,872
- Net Income
- $-3,522,072+73.3%
- EPS
- $-0.07+76.4%
- OCF Growth
- +20.7%
- FCF Growth
- +24.3%
- 52W High
- $0.93
- 52W Low
- $0.36
- 50D MA
- $0.45
- 200D MA
- $0.59
- Beta
- 1.33
- RSI (14)
- 62
- Avg Volume
- 46.88K
No earnings-call transcripts are available for DTC.CN yet.
- Free Float
- 89.5%
- Shares Outstanding
- 75.79M
- Float Shares
- 67.83M
Our DTC.CN coverage
Recent articles, reports, and earnings notes.
No research on DTC.CN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DTC.CN report →